Before being added to the FCS inventory, CJ Biomaterials’ scPHA had to successfully complete extensive safety testing by the FDA. Basing its evaluation on Section 409 of the federal Food, Drug, and Cosmetic Act, the Agency determined that it is safe for its intended use.
“The addition of our PHACT S1000P technology to the FDA Inventory of Effective Food Contact Substances demonstrates CJ Biomaterials’ commitment to safety and innovation,” says Max Senechal, Chief Commercial Officer for CJ Biomaterials. “We are continuing to move forward to advance the applications and uses for our PHA technology, and we are proud that our technology is being used to help address the global challenge of plastic pollution. Adding our scPHA biopolymers to the FCS inventory will allow us to expand the impact we can make.”